Skip to main content
Funded Studies

Tiago Outeiro, PhD

Principal Investigator at Institute for Molecular Medicine

Location: Lisbon Portugal

Dr. Tiago Outeiro graduated in Biochemistry at the University of Porto and was an Erasmus student at the University of Leeds in the UK. Dr. Outeiro then did his PhD thesis at the Whitehead Institute for Biomedical research – MIT. Next, he worked at FoldRx Pharmaceuticals as a Research Scientist and Consultant. His work consisted of transferring the technology he and Dr. Susan Lindquist developed and patented during his PhD. Dr. Outeiro was a Postdoctoral Research Fellow in the Department of Neurology of the Massachusetts General Hospital – Harvard Medical School where he focused on the study of Neurodegenerative disorders such as Parkinson’s and Alzheimer’s disease. Dr. Outeiro was a co-founder of BioEPI Clinical and Translational Research Center, a start-up company in Portugal. Dr. Outeiro has given several invited lectures in the USA and in Portugal and has organized several international scientific meetings and courses both in Portugal and abroad, with the participation of many of the leaders in the field of neurodegeneration. Dr. Outeiro served as an expert evaluator for the VI Framework Program of the European Commission.

Dr. Outeiro is now a Principal Investigator at the Institute for Molecular Medicine in Lisbon, where he investigates the molecular mechanisms involved in neurodegenerative diseases associated with protein misfolding, with the goal of developing novel avenues for therapeutic intervention. He also maintains a visiting scientist position at the Massachusetts General Hospital, Harvard Medical School, USA.

Associated Grants

  • Deciphering the Molecular Effects of Alpha-Synuclein in the Nucleus: DNA Binding and Transcriptional Dysregulation


  • Unraveling the Genetic Basis for Alpha-Synuclein Oligomerization in Living Cells Using Bimolecular Fluorescence Complementation


  • Unraveling the genetic basis for alpha-synuclein oligomerization in living cells using bimolecular fluorescence complementation


  • Validation of Sirtuin 2 Deacetylase as a Therapeutic Target in Parkinson’s disease


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.